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doi:10.1Objective: Cilnidipine is a novel, long-action L/N-type dihydropyridine calcium channel blocker that has re-
cently been used for antihypertensive therapy.We investigated the vasorelaxation effect of cilnidipine with regard
to its calcium channel blockage and nitric oxide-cyclic guanosine monophosphate-dependent mechanism in hu-
man internal thoracic artery.
Methods: Fresh human internal thoracic arteries taken from discarded tissues of patients undergoing coronary
artery bypass surgery were studied. Concentration-relaxation curves for cilnidipine in comparison with nifedipine
were studied. The expression level of endothelial nitric oxide synthase mRNA was assayed by quantitative real-
time polymerase chain reaction, and the phosphorylation of endothelial nitric oxide synthase at Ser1177 was
determined by Western blotting analysis.
Results: Cilnidipine and nifedipine caused nearly full relaxation in potassium-precontracted internal thoracic
artery. Pretreatment with cilnidipine at the clinical plasma concentration significantly depressed the maximal con-
traction. Endothelium denudation (47.7%  7.0%, P< .05) and inhibition of endothelial nitric oxide synthase
(48.6%  6.1%, P< .05) or guanylate cyclase (41.6%  3.8%, P< .01) significantly reduced the cilnidipine-
induced endothelium-dependent relaxation (73.9% 6.4%). Cilnidipine increased the expression of endothelial
nitric oxide synthase mRNA by 42.4% (P<.05) and enhanced phosphorylation level of endothelial nitric oxide
synthase at Ser1177 by 37.0% (P< .05).
Conclusions: The new generation of calcium channel antagonist cilnidipine relaxes human arteries through
calcium channel antagonism and increases production of nitric oxide by enhancement of endothelial nitric oxide
synthase. The dual mechanisms of cilnidipine in human arteries demonstrated in this study may prove particularly
important in vasorelaxing therapy in cardiovascular diseases. (J Thorac Cardiovasc Surg 2011;141:1063-9)The use of arterial grafts is common practice in coronary sur-
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SIn its extreme form, vasospasm of the ITA may cause serious
ischemic problems that are a long-recognized life-threatening
complication after coronary artery bypass grafting (CABG).4
Vasospasm is still a recognized problem in current practice
even in off-pump CABG.5 Because of the serious conse-
quences of vasospasm, the method to prevent and treat spasm
in ITA has been an important topic of research.6-9
Calcium (Ca2þ) channel blockers are commonly used cor-
onary vasodilators to effectively prevent or reverse spasmand
associated complications by decreasing vascular resistance
and increasing coronary blood flow and myocardial oxygen
supply.10 Dihydropyridine calcium channel blockers have
been demonstrated to have an excellent vasorelaxing effect
in human ITAs.9 However, the clinical benefits of the first-
generation dihydropyridine, such as nifedipine (NIF), may
be attenuated by the reflex tachyarrhythmia and increased an-
gina.11 Cilnidipine (CIL),10,12 a second-generation dihydro-
pyridine, has been used in patients as an antihypertensive
vasodilator. CIL exhibits better clinical benefits because of
its dual blocking effect on L-type voltage-gated Ca2þchannel
in vascular smooth muscle and N-type Ca2þ channel in
sympathetic nerve terminals that supply blood vessels.10,13
More recently, it has been demonstrated that CIL maydiovascular Surgery c Volume 141, Number 4 1063
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Sstimulate release of nitric oxide (NO) from the vascular
endothelium.14,15 It is possible that this new-generation dihy-
dropyridine derivative may have a particular vasodilatory
benefit in antispastic therapy. However, the vasorelaxant
effects of CIL and the underlying mechanisms in human
arteries are unknown.
The purpose of this study was therefore to assess the effi-
cacy and mechanisms of vasorelaxation of CIL in human
arteries. Particular interest was paid to test the hypothesis
that the NO-related mechanism of CIL may be due to the en-
hancement of endothelial nitric oxide synthase (eNOS) in
human arteries.MATERIALS AND METHODS
Organ Bath Technique
ITA segments (n¼ 102) were collected from 54 patients (42 men and 12
women with a mean age of 64.7 0.8 years) undergoing CABG. Approval
to use discarded ITA tissue was given by the institutional review board of
Providence St Vincent Hospital. All ITA specimens were collected and
placed in the container with oxygenated ice-cold Krebs solution and then
delivered to the laboratory. The Krebs solution was composed of (in milli-




- 1.2, and glucose 11, which was aerated with a gas mixture of
95% O2 and 5% CO2 at 37
C  0.1C during the period of experiment.
The details of collecting, dissecting, and mounting the ITA rings, and the
organ bath technique, have been described.9 Briefly, after cautiously dissect-
ing andmounting, the ringswere stretchedup inprogressive steps to determine
the length–tension curve for each ring. A computer iterative fitting program
(VESTAND 2.1; Yang-Hui He, Princeton, NJ) was used to determine the ex-
ponential line, pressure, and internal diameter. When the transmural pressure
on the rings reached100mmHg, as determined from their own length–tension
curves, the stretch-up procedure was stopped, and the rings were released to
90% of their internal circumference at 100mmHg.This degree of passive ten-
sion was then maintained throughout the experiment.
After at least 60 minutes of equilibration in the organ bath, 100 mmol/L
Kþwas added to the organ bath. The contraction magnitude of the ITA rings
was recorded, and the organ bath was then washed with Krebs solution until
the resting force was back to the baseline.
RNA Extraction, Polymerase Chain Reaction, and
Quantitative Reverse Transcription-Polymerase
Chain Reaction
ITA tissues were homogenized in TRIzol reagent (Invitrogen, Carls-
bad, Calif), and total RNA was isolated according to the manufacturer’s1064 The Journal of Thoracic and Cardiovascular Surspecifications. The quality and concentration of the RNA were determined
by measuring the absorbance at 260 and 280 nm afterward.
Real-time quantitative polymerase chain reaction (PCR) was used to
quantify eNOS mRNA expression level. RNA samples of 1 mg were pre-
pared for real-time PCR by random primed RT reaction using random hex-
amer primers (Promega Corp, Madison, Wis), and the reaction was then
diluted 1:10 for PCR quantification, which was conducted in triplicate
for increased accuracy. Ten microliters of reaction mixture contained
5 mL TaqMan Universal PCR Master Mix, 0.5 mL Abi eNOS primer and
probe mixture, 0.08 mL 18s RNA gene primers and 0.25 mL 18s RNA
probe, 2.09 mL diethylpyrocarbonate water, and 2 mL cDNA. The amplifi-
cation was performed as follows: 2 minutes at 50C, 10 minutes at 95C,
and then 45 cycles for 15 seconds at 95C and 60 seconds at 60C in the
ABI PRISM 7900 Sequences Detector Biosystem (PE Applied Biosys-
tems, Foster City, Calif). After PCR was completed, baseline and threshold
values were set to optimize the amplification plot, and the data were ex-
ported to an Excel spreadsheet (Microsoft Corp, Redmond, Wash). Stan-
dard curves were drawn on the basis of the log value of the input RNA
versus the critical threshold cycle, under which the critical threshold value
could be converted to relative RNA concentration for each sample and nor-
malized by 18s. Values of RNA concentration were finally expressed as
fold over control.16
Western Immunoblotting
ITA samples were homogenized in RIPA Lysis Buffer (Santa Cruz Bio-
technology, Inc, Santa Cruz, Calif), and the lysates were sonicated in ice for
30 minutes followed by 20 minutes of centrifugation at 20,000g. The super-
natant was then collected, and the protein concentration was assayed at
595 nm using the Cary 50 Bio UV-visible spectrophotometer (Varian,
Inc, Palo Alto, Calif). After heating the sample for denature at 75C for
10 minutes, 40 mg protein for each sample was separated by 8% PAGE
gel (PAGEgel, Inc, San Diego, Calif) together with the BenchMark pre-
stained protein ladder (Invitrogen, Carlsbad, Calif). The proteins were trans-
ferred electrophoretically to the transfer membrane (Millipore, Chelmsford,
Mass). The membrane was blocked with SuperBlock blocking buffer
(Pierce, Rockford, Ill) for 1 hour at room temperature and incubated with
primary antibody against eNOS phosphorylated at Ser1177 (1:1000) from
Upstate (Charlottesville, Va) overnight at 4C. Equivalent protein on the
same lane was confirmed by stripping and reblotting with b-actin
(1:20,000; SigmaAldrich, St Louis,Mo). The secondary goat anti-rabbit an-
tibody conjugated to horseradish peroxidase (Jackson ImmunoResearch
Laboratories, Inc, West Grove, Pa) at a dilution of 1:10,000 was added
the next day. Finally, the membrane was developed with Western Lightning
chemiluminescence Reagent Plus detection system (enhanced chemilumi-
nescence reagents; PerkinElmer LAS, Inc, Boston, Mass) and exposed on
x-ray films (Kodak, Rochester, NY). Intensity of the protein bands was
quantified byQuantity One software (Bio-Rad, Hercules, Calif) and normal-
ized by b-actin and expressed as fold over control.
Protocol
The ITA segments were randomly allocated in various groups to avoid
possible influence from patients’ demographics.
Relaxation
Cumulative concentration (105.5 logM)– relaxation curves for CIL
and NIF were established in ITA rings precontracted with Kþ (40 mmol/L,
n ¼ 6), U46619 (10 nM, n ¼ 6), or norepinephrine (NE, 10 mmol/L,
n ¼ 7). The concentration of the vasoconstrictors Kþ, U46619, and NE was
determined from previous studies. Only 1 concentration-relaxation curve
was obtained from each ITA ring. Relaxations to CIL and NIF (10 
5.5 log M) were recorded and expressed as a percentage of the
vasoconstrictor-induced precontraction. Another group of ITA rings con-
tracted by NE (10 mmol/L, n ¼ 6) was studied as time control because of






















Fan et al Evolving Technology/Basic ScienceDepression of the Contraction by Pretreatment With
Plasma Concentration of Cilnidipine in Internal
Thoracic Artery Rings
After equilibration of ITA rings for at least 60 minutes, 100 mmol/L Kþ
was added to the organ bath and the contraction force was recorded. The
rings were then repeatedly washed with Krebs solution to restore the base-
line. To determine whether pretreatment with CIL would alter the contrac-
tion response to Kþ, ITA rings were incubated with CIL (20 or 200 nM, or
vehicle) for 30 minutes. These concentrations were determined by previous
studies in which the plasma CIL concentrations after administration of 10
mg were in the range of 10 to 30 nM.17 Therefore, we chose 20 nM as
the plasma concentration to test the effect in ITA rings. In addition, a 10-
fold higher concentration (200 nM) that may be reached after bolus admin-
istration was also tested.17
Cumulative concentration-contraction curves for Kþ (10˜ 100 mmol/L)
were then reconstructed. Only 1 concentration-contraction curve was ob-
tained from each ring. The ITA ring taken from the same patient without
pretreatment of CIL served as control. Contractions to Kþ (10˜ 100 mmol/




















Nitric Oxide-cGMP Pathway-Dependent Relaxation
To investigate the role of endothelium denudation, endothelium-derived
NO and eNOS, or NO-related cGMP mechanism, CIL (30 nM)-induced re-
laxation in 40 mmol/L Kþ-induced precontraction was examined in
endothelium-denuded ITA rings; the endothelium-intact rings were pre-
treated with NO synthase inhibitor L-NNA (300 mmol/L) or guanylate cy-
clase inhibitor ODQ (3 mmol/L) for 180 minutes. Endothelium-intact ITA
rings taken from the same patient were studied as control. These control
rings were also contracted with 40 mmol/L Kþ for 180 minutes. To exclude
the effect of the solvent (dimethyl sulfoxide) of CIL (30 nM), the equal
amount of dimethyl sulfoxide was added to the bath after 40 mmol/L Kþ.
In the endothelium-denuded ITA rings, the endotheliumwas removed by











EExpression of Endothelial Nitric Oxide Synthase
The artery segment, taken from the same patient undergoing CABG, was
divided into 4 rings and randomly assigned to 4 groups as follows: CIL
group (incubated with 3 mmol/L CIL for 4 hours); NE group (incubated
with 10 mmol/L NE for 4 hours); CIL þ NE group (incubated with
10 mmol/L NE for 30 minutes followed by 3 mmol/L CIL for 4 hours);
and control group (incubated with vehicle). All arteries were then flash-
frozen in liquid nitrogen and stored at80C for further study.
RNA in ITA tissue was extracted as described. Then, 1 mg RNA samples
were prepared for reverse transcription, and 2 mg cDNA were used to per-
form real-time PCR to quantify eNOS mRNA expression level.50
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FIGURE 1. Mean concentration (log M)/relaxation (%) curves for CIL
and NIF in human ITA rings precontracted with (A) potassium chloride
(Kþ, 40 mmol/L, n ¼ 6), (B) U46619 (10 nM, n ¼ 6), and (C) NE
(30 mmol/L, n ¼ 7). Values are expressed as mean  standard error (SE).
P> .05, compared with each other (1-way analysis of variance followed





SPhosphorylation of Endothelial Nitric Oxide
Synthase at Ser1177
The artery segment, taken from the same patient undergoing CABG, was
divided into 3 rings and randomly assigned to 3 groups as follows: CIL
group (incubated with 10 mmol/L NE for 15 minutes followed by 3 mmol/
L CIL for 10 minutes); bradykinin (BK) group (incubated with 10 mmol/
L NE for 15 minutes followed by 50 nM BK for 5 minutes); and control
group (incubated with 10 mmol/L NE for 15 minutes followed by incubation
with vehicle of CIL). BK was used to stimulate the eNOS expression be-
cause it is a classic endothelium-dependent vasodilator known to increase
eNOS and NO release. All arteries were then flash-frozen in liquid nitrogen
and stored at80C for further study.
As mentioned earlier, protein in ITA tissue was extracted with RIPA
buffer. Then, 40 mg protein samples were separated by 8% PAGE gel
and transferred electrophoretically to the transfer membrane. After beingThe Journal of Thoracic and Carincubated with primary and secondary antibodies, the membrane was ex-
posed on x-ray films. Densitometry was then performed for the band to























FIGURE 2. Mean concentration (logM)/contraction (%) curves for potas-
sium chloride (Kþ, 10 100 mmol/L) in the human ITA rings pretreatment
with CIL (6.7 and7.7 logM). Values are expressed as mean SE, n ¼ 6.



































































FIGURE 3. Time (minutes)/relaxation (%) curves for CIL (30 nM) in
endothelium-intact (n ¼ 7) and denuded (n ¼ 7) ITA rings with or without
ODQ (3 mmol/L, n¼ 8) or L-NNA (300 mmol/L, n¼ 8) precontracted with
40 mmol/L potassium chloride (Kþ). Endothelium-intact ITA rings taken
from the same patient were studied as control. These control rings were
also contracted with 40 mmol/L Kþ for 180 minutes. To exclude the effect
of the solvent (dimethyl sulfoxide) of CIL (30 nM), the equal amount of di-
methyl sulfoxide was added in the bath of these control rings after 40 mmol/
L Kþ. Values are expressed as mean  SE. *P< .05, **P< .01, compared
with endothelium-intact control group.





BK, L-NNA, ODQ, NIF, and NE were purchased from Sigma-Aldrich
(St Louis, Mo). CIL was a gift from Fujirebio (Tokyo, Japan). U46619 was
purchased from Cayman Chemical Company (Philadelphia, Pa); stock
solutions were held at20C. Stock solutions of CIL and NIF at concentra-
tion of 0.1 mol/L were diluted in dimethyl sulfoxide and kept frozen until
required.
Statistical Analyses
The relaxation effect of CIL and NIF was recorded and expressed as
a percentage of the vasoconstrictor-induced precontraction. Statistical
comparisons of the maximal percentage relaxation, expression level of
eNOS mRNA, and phosphorylation of eNOS at Ser1177 under different
treatments were performed by 1-way analysis of variance followed by
Bonferroni’s comparison test. Statistical comparisons of cumulative con-
traction force and cumulative percentage of relaxation under different treat-
ments were performed by 2-way analysis of variance followed by
Bonferroni’s test.
The efficacy of both vasoconstrictors and vasodilators was expressed as
EC50, the effective concentration causing 50% of maximal contraction or
relaxation. The EC50 was determined from each concentration-contraction
or concentration-relaxation curve by a logistic curve-fitting equation:
E¼MAP/(APþKP), where E is response, M is maximal contraction or relax-
ation, A is concentration, K is EC50 concentration, and p is the slope param-
eter. A computerized program was used for the curve fitting. EC50 values
between different groups were analyzed by unpaired t test. All values
were expressed as mean  standard error.
RESULTS
Resting Parameters of Internal Thoracic Artery
Rings in Contraction or Relaxation Studies
The internal diameter of the 73 vessels at an equivalent
transmural pressure of 100 mm Hg (D100) was 2.45 
0.06 mm, as determined from the computerized normaliza-
tion procedure. The resting transmural pressure was
74.7  0.7 mm Hg at 90% of D100. The resting force of
the ITA rings was 3.2  0.2g.1066 The Journal of Thoracic and Cardiovascular Surgery c April 2011










































FIGURE 4. Expression of eNOS mRNA in human ITA rings treated with
3 mmol/L CIL (n¼ 6), 10 mmol/L NE (n¼ 6), 3 mmol/L CIL, and 10 mmol/L
NE (n¼ 5), for 4 hours, assayed by quantitative real-time PCR. The level of
eNOS expression was normalized by 18s and expressed as fold over control.
Values are expressed as mean SE, n¼ 5, 6. *P<.05, compared with con-
trol. CIL,Cilnidipine;NIF, nifedipine;NE, norepinephrine; eNOS, endothe-
lial nitric oxide synthase.
       CIL     Control        BK      
peNOS      132 KDa 
eNOS     135 KDa 






* p < 0.05






















FIGURE 5. eNOS and phosphorylation of eNOS at Ser1177 in human ITA
stimulated with 10 mmol/L NE for 15 minutes followed by 10-minute incu-
bation with 3 mmol/L CIL (n ¼ 6) or 5-minute incubation with 50 nM BK
(n ¼ 6), examined by Western blot analysis. Incubation with vehicle was
used as control. A, Representative Western blot abundance depicting
eNOS and the phosphorylation of eNOS at Ser1177. Photographs were mod-
ified by Photoshop software (Adobe Systems Inc, San Jose, CA) with the
same brightness and contrast. B, Optical density of eNOS phosphorylated
at Ser1177, normalized by ß-actin and expressed as fold over control. Values
are expressed as mean  SE. *P< .05, **P< .01, compared with control.
peNOS, Phosphorylation of eNOS; eNOS, endothelial nitric oxide synthase;
CIL, cilnidipine; BK, bradykinin.
Fan et al Evolving Technology/Basic ScienceSimilar Relaxation Effect of Cilnidipine and
Nifedipine in Human Internal Thoracic Artery Rings
Precontracted With Kþ, U46619, and Norepinephrine
CIL and NIF-induced relaxation were studied in human
ITA rings precontracted with different vasoconstrictors:
Kþ (40 mmol/L, n ¼ 6), U46619 (10 nM, n ¼ 6), and NE
(10 mmol/L, n ¼ 7). CIL and NIF caused nearly full relaxa-
tion (94.7%  2.6% vs 100%  0%) with similar EC50s
(8.90  0.90 log M vs8.46  1.08 log M) in Kþ-precon-
tracted ITA rings and less relaxation (82.4%  8.1% vs
84.5%  9.9%; EC50s:7.50  0.44 log M vs7.43 
0.41 log M, P¼ .19 for CIL and P ¼ .39 for NIF, compared
with Kþ-induced precontraction) in U46619-precontracted
ITA rings. In ITA rings precontracted with NE, because
the contraction was unstable, the relaxation was adjusted
by the time control in the ring, which was contracted by
NE, but no vasodilators were tested. The relaxation was sig-
nificantly less in NE precontraction (36.3%  6.2% vs
40.4%  3.9%; EC50: 6.55  0.69 log M vs 6.68 
0.47 log M, P¼ .06 for CIL and P ¼ .14 for NIF, compared
with Kþ-induced precontraction) (Figure 1).E
T
/B
SDepression of the Contraction by Pretreatment With
Plasma Concentration of Cilnidipine in Internal
Thoracic Artery Rings
After incubating CIL (20, 200 nM) for 30 minutes, cumu-
lative concentration-contraction curves to Kþ in ITA rings
with and without CIL incubation were established, and the
contraction was expressed as percentage of the contraction
to 100 mmol/L Kþ (Figure 2). Pretreatment with 20 nM CIL
slightly altered Kþ-induced contraction force (88.7% 
10.2% vs 100.8%  11.0%, P > .05) and the EC50s
(29.3  18.7 mmol/L vs 36.4  12.3 mmol/L, P> .05).The Journal of Thoracic and CarFurther, CIL at the concentration of 200 nM significantly
reduced the magnitude of the contraction induced by Kþ at
concentration from 40 to 100 mmol/L and right-shifted the
curve compared with the control group (EC50: 95.0  21.5
mmol/L vs 36.4 12.3 mmol/L, P<.01). The maximal con-
traction force induced by Kþ was 59.2% of the control
(59.7%  6.7% vs 100.8%  11.0%, P< .01).Cilnidipine-Induced Relaxation Is Altered by
Endothelium-Denudation, L-NNA, or ODQ: The
Role of the Nitric Oxide-cGMP Pathway
In 40 mmol/L Kþ-induced contraction, CIL-induced re-
laxation was significantly attenuated by denudation of endo-
thelium at 180 minutes (47.7% 7.0% vs 73.9% 6.4%,
P < .05, Figure 3, A). A similar effect was seen in
endothelium-intact ITA rings pretreated with 300 mmol/L
L-NNA (48.6%  6.1% vs 73.9%  6.4%, P < .05,
Figure 3, B). When the endothelium-intact ITA rings were
incubated with 3 mmol/L ODQ (guanylate cyclase inhibitor),
the magnitude of CIL-induced relaxation was depressed
even more dramatically during the whole observation period
(41.6%  3.8% vs 73.9%  6.4%, P< .01, Figure 3, C).diovascular Surgery c Volume 141, Number 4 1067




SExpression Level of Endothelial Nitric Oxide
Synthase mRNA in Human Internal Thoracic Artery
Tissue
The expression level of eNOS mRNA in ITA tissue stim-
ulated with 10 mmol/L NE for 30 minutes followed by
3 mmol/L CIL incubation for 4 hours was increased obvi-
ously by 42.4% (1.0  0.1 vs 1.4  0.2, P < .05)
(Figure 4). However, treatment with CIL or NE had no sig-
nificant effect on the expression level of eNOS mRNA.Enhanced Phosphorylation of Endothelial Nitric
Oxide Synthase at Ser1177 in Human Internal
Thoracic Artery Tissue
In human ITA stimulated by 10 mmol/L NE for 15minutes
followed by the incubation with 3 mmol/L CIL for 10 min-
utes or 50 nM BK for 5 minutes, the phosphorylation of
eNOS at Ser1177 increased dramatically (Figure 5, A). In con-
trast, there was no significant change in eNOS (Figure 5, A).
The optical density value for CIL-treated tissues was in-
creased by 37.0% (P< .05) in comparison with control
(Figure 5, B).DISCUSSION
The present study found that (1) CIL is an effective
vasodilator in the human ITA, and this provides important
information for clinical use of this new generation of dihydro-
pyridine; (2) CIL has dualmechanisms in the relaxation effect,
including calcium channel inhibition and endothelium-
dependent mechanism; and (3) unlike traditional calcium an-
tagonists, CIL enhances eNOS expression, which may open
a new direction in the development of new vasodilators.
It is now well known that calcium is the principal media-
tor involved in vasomotion19 and that influx of Ca2þ through
the L-type calcium channel triggers cell contraction and is
inhibited by calcium channel blockers.20,21
Available oral calcium channel blockers as antihyperten-
sive drugs are classified into 4 categories or generations.22,23
CIL is a long-acting N-type calcium channel blocker, and it
is considered a fourth-generation calcium channel blocker
that suppresses the activity of the sympathetic nervous sys-
tem via the N-type calcium channel.23 Therefore, compared
with other calcium channel blockers, apart from its ability to
lower blood pressure, the particular benefits of CIL are sig-
nificant suppression of increases in heart rate, epinephrine,
and NE.24 These benefits may make CIL clinically useful
in patients with coronary artery disease and combined hyper-
tension, which is one of the major risk factors for coronary
artery disease.
It is suggested that CIL14,15 may release NO from vascular
endothelium in animal vessels. However, this has not been
demonstrated in human vessels. In the present study, the
NO-stimulating effect of CIL is demonstrated by the
endothelium-dependent relaxation induced by CIL, as well1068 The Journal of Thoracic and Cardiovascular Suras the reduction of the relaxation by eNOS inhibitor
L-NNA and the soluble guanylate cyclase inhibitor ODQ.
The molecular studies also support the hypothesis that
CIL up-regulates eNOS mRNA and protein production.
When the vessel was incubated with CIL and NE, the in-
crease of eNOS mRNA was significant, although the effect
of CIL alone was weak. In the study on the eNOS protein,
the increase of the protein was as significant as the classic
eNOS stimulant BK that clearly shows the enhancement of
eNOS by CIL. This is particularly important when there is
endothelial dysfunction, as in patients with coronary artery
disease. There is often associated endothelial dysfunction
in various vasculatures, and frequently associated diseases,
such as diabetes and hypertension, are also accompanied
by endothelial dysfunction.
These studies clearly demonstrated the dual mechanisms
of CIL in the human vessels used as coronary artery bypass
grafts and therefore support the use of this fourth-generation
calcium channel blocker for coronary artery disease because
this drug may relax the coronary artery by a direct relaxing
effect and enhancement of the NO-related endothelial func-
tion. Endothelial dysfunction is an early sign of coronary ar-
tery disease.25,26
Finally, unlike NIF, which can be used only orally, CIL
can be used orally or intravenously,27 and therefore can be
used topically during surgery as a topical antispastic solution.
CONCLUSIONS
The new generation of calcium channel antagonist CIL
relaxes human arteries through calcium channel antagonism
and increased production of NO by enhancement of eNOS.
The dual mechanisms of CIL in human arteries demon-
strated in this study may prove particularly important in
vasorelaxing therapy in cardiovascular diseases.
The authors thank the surgical team and the nurses in the Cardio-
vascular Operation Room of Providence St Vincent Medical Center
for assistance in collecting the human ITA tissue.
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